Article
Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Functional & integrative genomics - 31 Jan 2023
Yin Zhao, Liao Meiyan, Yan Rongrong, Li Guangchao, Ou Ruiming, Liu Zhi, Zhong Qi, Shen Huijuan, Zhu Yangmin, Xie Shuangfeng, Zhang Qing, Liu Shuang, Huang Jing
Abstract excerpt
Olverembatinib represents the third-generation breakpoint cluster region protein-Abelson-murine leukemia 1 (BCR-ABL1) tyrosine kinase inhibitor with oral bioavailability, which can be used to overcome the T315I mutation in Philadelphia chromosome-positive (Ph +) leukemia. BCR-ABL-independent resistance to olverembatinib has been reported among patients in various clinical cases. However, the mechanism of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.